German China

Development and Manufacturing Agreement Partnership for Development of Anti-HIV and Anti-SARS-CoV-2 Therapies

Editor: Alexander Stark

Samsung Biologics and Enzolytics announced the signing of a strategic CDMO partnership agreement for the development and manufacturing of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

Samsung Biologics is a fully integrated CDMO.
Samsung Biologics is a fully integrated CDMO.
(Source: Samsung Biologics)

College Station/USA; Incheon/South Korea — Under the terms of an agreement between Samsung Biologics and Enzolytics, the South Korean company will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics.

The Enzolytics protocol offers the opportunity to implement AI analysis and provides a platform for creating multiple fully human Monoclonal Antibodies targeting conserved immutable sites on the virus and offering a cure for these viruses. A stable cell line will be manufactured with support from Samsung Biologics' R&D Center in San Francisco. Its related clinical trial materials will be manufactured at Samsung Biologics headquarters in Incheon, South Korea.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent